Brenig Therapeutics, Inc.
Dover, US · Founded 2021 · Delaware corporation · 1 known investors
Biotech
Founders & leadership
ID
Iain DukesNamed on SEC filing
NS
Nikolay SavchukNamed on SEC filing
Board
KG
Keno GutierrezBoard director
EM
Edward MathersBoard director
MC
Michele CuculluBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$30M disclosed across 1 round · 2024
▶$30MraisedJul 2024 · 6 investors · BiotechnologyRule 506(b)
▶$30MraisedJul 2024 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Keno GutierrezDirector
- Iain DukesExecutive Officer, Director
- Edward MathersDirector
- Nikolay SavchukExecutive Officer, Director
- Michele CuculluDirector
- Offering amount
- $65M
- Amount sold
- $30M
- First sale
- Jul 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- Who are Brenig Therapeutics, Inc.'s investors?
- Brenig Therapeutics, Inc.'s investors include NEA Secondary.
- How much funding has Brenig Therapeutics, Inc. raised?
- Brenig Therapeutics, Inc. has disclosed $30M raised across 1 round.
- Where is Brenig Therapeutics, Inc. headquartered?
- Brenig Therapeutics, Inc. is headquartered in Dover, US.